142148-13-8

Usage

Uses

Used in Pharmaceutical Industry:
(1-HYDROXYMETHYL-CYCLOPROPYL)-ACETIC ACID METHYL ESTER is used as a building block for the synthesis of various pharmaceuticals, due to its ability to contribute to the development of new drugs for the treatment and prevention of a range of diseases.
Used in Agrochemical Industry:
In the agrochemical sector, (1-HYDROXYMETHYL-CYCLOPROPYL)-ACETIC ACID METHYL ESTER is utilized as a component in the formulation of agrochemicals, potentially enhancing crop protection and yield through its antifungal and antibacterial properties.
Used in Fragrance and Flavoring Industry:
(1-HYDROXYMETHYL-CYCLOPROPYL)-ACETIC ACID METHYL ESTER is employed as a key ingredient in the production of fragrances and flavorings, capitalizing on its distinctive chemical structure to create novel scents and tastes for consumer products.

InChI:InChI=1/C7H12O3/c1-10-6(9)4-7(5-8)2-3-7/h8H,2-5H2,1H3

Upstream product

• 186581-53-3 diazomethane 
• 67-56-1 methanol 
• 33867-36-6 5-oxaspiro[2.4]heptan-6-one 
• 124-41-4 sodium methylate 
• 152922-71-9 1-(hydroxymethyl)cyclopropaneacetonitrile 
• 39590-81-3 [1-(hydroxymethyl)cyclopropyl]methanol 
• 64-19-7 acetic acid 
• 869066-83-1 2‐[1‐(hydroxymethyl)cyclopropyl]acetic acid 

Downstream Products

• 855473-50-6 1-bromomethylcyclopropyl acetic acid methyl ester 
• 152922-71-9 1-(hydroxymethyl)cyclopropaneacetonitrile 
• 338392-48-6 2-(1-(bromomethyl)cyclopropyl)acetonitrile 
• 162515-68-6 1-(sulfanylmethyl)cyclopropaneacetic acid 
• 1087347-36-1 tert-butyl (3R,4S)-3-{[[3-({1-[2-(benzyloxy)-2-oxoethyl]cyclopropyl}methoxy)-5-(3-methoxypropyl)benzyl](cyclopropyl)amino]carbonyl}-4-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}piperidine-1-carboxylate 
• 1087347-35-0 (1-{[3-{[[((3R,4S)-1-(tert-butoxycarbonyl)-4-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}piperidin-3-yl)carbonyl](cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenoxy]methyl}cyclopropyl)acetic acid 
• 1087347-34-9 tert-butyl (3R,4S)-3-({(cyclopropyl)[3-{[1-(2-methoxy-2-oxoethyl)cyclopropyl]methoxy}-5-(3-methoxypropyl)benzyl]amino}carbonyl)-4-{4-[2-(2.,6-dichloro-4-methylphenoxy)ethoxy]phenyl}piperidine-1-carboxylate 
• 142148-14-9 methyl 1-(acetylthiomethyl)cyclopropylacetic acid 

Relevant academic research and scientific papers

DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES

Provided are dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

Montelukast side chain intermediate and preparing method thereof

The invention belongs to the field of medical chemistry, and particularly relates to a montelukast side chain intermediate and a preparing method thereof. A provided intermediate compound is 6-halogenated methyl-5,7-dioxaspiro[2,5] octane, wherein 1,1-cyclopropyl dimethyl carbinol serving as a starting material and 2-halogeno-1,1-dimethoxyethane are subjected to a transacetalation reaction under solid acid catalysis to obtain 6-halogenated methyl-5,7-dioxaspiro[2,5] octane, the intermediate is treated with organic alkali and then hydrolyzed with a water solution containing acetic acid to obtain monoacetylated protected diol. The problems that monoacetylated protected diol is poor in selectivity, and diol loss is serious are solved, the availability of the raw materials is improved, and the montelukast side chain intermediate can be synthesized economically and conveniently.

NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS

The invention is related to compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, ester, and/ or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

NOVEL CASE OF RENIN INHIBITORS

The present invention relates to piperidine-based renin inhibitor compounds having carboxylate or carboxylic acid terminal groups. The disclosed low molecular weight, orally active renin inhibitors are of non-peptide nature and have long duration of action. The compounds can be used in the treatment of cardiovascular events and renal insufficiency.

Process for making montelukast and intermediates therefor

A process for making montelukast, a pharmaceutically useful compound of the following formula and salts thereof: using a compound of formula (20) is provided.

Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists

Compounds having the formula I: STR1 are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.

SATURATED HYDROXYALKYLQUINOLINE ACIDS AS LEUKOTRIENE ANTAGONISTS

Compounds having the formula I: STR1 are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.

QUINOLINE-CONTAINING KETOACIDS AS LEUKOTRIENE ANTAGONISTS

Compounds having the formula I: STR1 are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis and allograft rejection.

Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists

Compounds having the formula I: STR1 are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.